Can Dr Reddy’s shrug off Revlimid’s patent expiry?
DRL also faces headwinds because of increasing competitive intensity in the generic market and exchange rate volatility.
Health Rounds: Fewer post-surgery complications found in diabetes patients taking GLP-1 drugs
Hello, Health Rounds Readers! Today we feature a study that found yet another potential health benefit of GLP-1 drugs, this ...
offalyexpress.ie1d
Offaly project on weight loss drug entered in Young Scientist Exhibition
There are five projects from Tullamore College. 'Perimenopause Uncovered: Empowering women through knowledge' was entered by ...
STAT1d
Pharmalittle: We’re reading about FDA commish’s parting thoughts, a warning on RSV shots, and more
He also articulated a very specific doctrine about the role of an FDA commissioner, one that is limited in its power and ...
kffhealthnews1d
Johnson: No Social Security, Medicare Cuts To Fund Trump’s Priorities
"The Republican Party will not cut benefits," Republican House Speaker Mike Johnson said. Also in the news: Medicare drug price negotiations, the House transgender bathroom ban, and more.
Diabetes or diet? Ozempic’s double life as a weight-loss miracle
Can this diabetes-control breakthrough also become the answer to obesity? From Hollywood’s red carpets to affluent Indians, ...
Novo Nordisk Vs. Eli Lilly: Obesity Makes Their Future Bright, But One Of Them Has More Potential
Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.
FiercePharma6d
Novo asks FDA to restrict Victoza compounding amid GLP-1 outsourcing row
In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...